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ABSTRACT: Concerns have been raised that per-
sons with serious illnesses participating in high-risk
research, such as PD patients in sham surgery trials, have
unrealistic expectations and are vulnerable to exploita-
tion. A comparison of enrollees and decliners of such
research may provide insights about the adequacy of de-
cision making by potential subjects. We compared 61
enrollees and 10 decliners of two phase II neurosurgical
intervention (i.e., cellular and gene transfer) trials for PD
regarding their demographic and clinical status, percep-
tions and attitudes regarding research risks, potential
direct beneﬁt, and societal beneﬁt, and perspectives on
the various potential reasons for and against participa-
tion. In addition to bivariate analyses, a logistic regression
model examined variables regarding risks and beneﬁts as
predictors of participation status. Enrollees perceived
lower risk of harm while tolerating higher risk of harm and
were more action oriented, but did not have more
advanced disease. Both groups rated hope for beneﬁt as
a strong reason to participate, whereas the fact that the
study’s purpose was not solely to beneﬁt them was rated
as ‘‘not a reason’’ against participation. Hope for beneﬁt
and altruism were rated higher than expectation of beneﬁt
as reasons in favor of participation for both groups.
Enrollees and decliners are different in their views and
attitudes toward risk. Although both are attracted to
research because of hopes of personal beneﬁt, this hope
is clearly distinguishable from an expectation of beneﬁt
and does not imply a failure to understand the main pur-
pose of research.VC 2012Movement Disorder Society
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apeutic misconception; decision making; gene transfer
The participation of patients with serious medical
conditions in research studies with signiﬁcant risks
remains controversial. Concerns continue to be raised
that those who enroll in such research are ‘‘unrealis-
tic’’ in their expectations.1 In PD research, studies
involving sham surgery controls have been particularly
controversial, with concerns that these older patients
with serious illnesses are being exploited.2 The con-
cern is that patients with serious illnesses are so des-
perate that they may be making less than optimal
decisions when they participate. Such concerns involve
claims about how patients make decisions regarding
research participation. Thus, understanding how
patients with PD, in fact, make decisions to participate
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in highly invasive studies provides important insights
into how informed consent for such studies can be
optimized.3 In this regard, a comparison of those who
agree to participate with those who decline to do so
may provide unique insights. For example, do those
who enroll in research have more advanced disease or
have more symptoms (perhaps making them more
‘‘desperate’’) than those who decline? Do enrollees
have a higher expectation of beneﬁt or lower expecta-
tion of risks than decliners? Or is it that the decliners
and enrollees have different values or attitudes toward
risks and potential beneﬁts?
In this study, we interviewed actual participants and
decliners of two industry-sponsored PD randomized,
clinical trials involving a sham surgery control and
compared them in the following ways. Are the groups
different in their demographic or clinical characteris-
tics? Do they view reasons for and against participation
differently? Do they have different perceptions and atti-
tudes regarding risks and beneﬁts of participation?
Patients and Methods
Participants
Participants were enrollees and decliners of two
early-phase intervention trials for PD. Enrollees were
persons who had enrolled and undergone the primary
study intervention. Decliners were individuals who dis-
cussed the trial with a member of the research team,
but who ultimately declined participation in the trial.
The STEPS trial was a multicenter phase II efﬁcacy
trial of an intervention utilizing human retinal pigment
epithelial cells that secrete levodopa (L-dopa).4 Sub-
jects were randomized to receive experimental injec-
tions bilaterally or a sham surgical procedure
involving bilateral incisions and full-thickness burr
holes. The trial enrolled 71 subjects across 10 sites;
ﬁve of those sites agreed to ask their enrollees and
decliners whether we could contact them about partic-
ipating in our interview study. We interviewed 31 of
56 (55%) enrollees at those sites and also 7 of 16
decliners (44%). The second study, the CERE-120
trial, was a randomized, clinical trial of a modiﬁed
adeno-associated virus vector with a gene for neu-
rturin.5 The sham surgery involved bilateral partial-
thickness burr holes. This study involved nine sites
across the United States; seven of nine sites agreed to
ask their enrollees and decliners whether we could
contact them, and we interviewed 30 of 43 enrollees
(70%) and also 3 of 9 decliners (33%).
As a result of sponsor requests, the time frame from
when enrollee subjects had their surgery to when their
interview was conducted differed across the two trials.
CERE-120 enrollees were approached for interviews
approximately 1 month after they had undergone sur-
gery. Twenty-six (86.7%) of the enrollee interviews
took place between 1 and 9 months after their sur-
gery; four interviews took place more than 9 months
after their surgery. Of the 3 decliners interviewed
from the CERE-120 study, 2 decliners were inter-
viewed less than 9 months after discussing the CERE-
120 study with the research team. At the request of
the sponsor, STEPS enrollees were approached after
the blind in the trial had been broken. Thus, for the
STEPS trial, seven (22.6%) interviews occurred less
than 2 years postsurgery, 10 (32.3%) interviews
between 2 and 4 years after surgery, and 14 (45.2%)
occurred greater than 4 years postsurgery. The
decliners were approached any time after they ofﬁ-
cially declined participation. Four decliners were inter-
viewed between 2 and 4 years after discussing the
STEPS study with researchers, whereas 3 were inter-
viewed less than 2 years after recruitment discussions.
The interviews were conducted by telephone and
were recorded and transcribed, except for one inter-
view for which interviewer notes were used because of
technical difﬁculties.
The institutional review boards of the University of
Rochester and the University of Michigan deemed the
study exempt from federal regulations.
Measures
This was part of a larger overall study that involved
both qualitative and quantitative measures. The results
of the qualitative analysis will be presented elsewhere.
Attitudes Toward and Perception of Risk and
Beneﬁts
We obtained a risk tolerance score by asking the
subjects how much risk, deﬁned as the likelihood of
one or more serious adverse events occurring to them,
that they would tolerate and still participate in their
respective clinical trial. Subjects were reminded of the
risks as follows: ‘‘The possible risks and discomforts
of participating in the [clinical trial] were described to
you by the research team conducting the trial and in
the informed consent you signed. Some of the risks
that were mentioned include: depression, hallucina-
tions or delusions, bleeding or blood clot in the brain,
seizures, dyskinesias, worsening of neurologic condi-
tion, infection, or heart attack.’’
The response was elicited using a ‘‘ping-pong’’
method.6 In this procedure, the interviewer elicits will-
ingness to participate at 0% risk, then goes to 100%
risk, then bounces back and forth in 10% increments
until the willingness to participate reverses; then, ﬁner
increments are used to arrive at the highest likelihood
of risk that they would tolerate. Persons not willing to
participate even at 0% risk were assigned a score of
1 to allow for nonparametric analyses.
A personal beneﬁt requirement score was elicited
using the same technique. Subjects were asked how
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much personal beneﬁt (deﬁned as the likelihood of
improving to the point where they could with medica-
tions ‘‘function almost normally with few side
effects’’) they would require for them to participate in
their respective trial. Persons not willing to participate,
even at 100% likelihood of beneﬁt, were assigned a
score of 101.
A societal beneﬁt requirement score was obtained by
asking the subjects how much societal beneﬁt, deﬁned
as researchers ﬁnding ‘‘a cure for PD within 10 years
as a result of the study,’’ they would require to partici-
pate, even if they knew they themselves would not
beneﬁt by participating. Persons not willing to partici-
pate, even at 100% likelihood of societal beneﬁt, were
assigned a score of 101.
Finally, subjects were asked for their perception of
likelihood of risk involved (‘‘what percent chance of
risk to yourself were you expecting?’’) and their per-
ceptions concerning the likelihood of beneﬁt to them-
selves and to society (‘‘what percent chance of beneﬁt
to yourself [or society] were you expecting?’’). These
scores are the subject’s risk perception score, personal
beneﬁt perception score, and societal beneﬁt percep-
tion score, each with a possible range of 0 to 100.
Ratings of Reasons For and Against Participation
This measure assesses a series of reasons related to
participation in a clinical trial—six reasons in favor of
participation and eight against participation—and
reﬂects how strong a factor each reason was in the de-
cision whether to participate in the respective clinical
trial.6 The response categories were ‘‘not a reason,’’
‘‘minor reason,’’ ‘‘moderate reason,’’ and ‘‘strong rea-
son.’’ These were given numeric scores of 1 through 4
for analysis.
Demographic and Clinical Background
Information
Basic demographic information (e.g., age, gender,
education, race and ethnicity, marital status, and
employment status) was collected. Background infor-
mation on the subject’s PD status was also collected
(i.e., number of years since diagnosis, ability to per-
form certain activities of daily living, and past
research participation).
Analysis
Descriptive data (i.e., means, medians, frequencies,
and percentages) were calculated. For demographic
variables, a two-group t test was used when testing
means and Fisher’s exact test was used to compare fre-
quency data. When comparing ordinal responses (i.e.,
reasons for and against participation) or probability
estimates between the enrollee and decliner groups
(i.e., the risk and beneﬁt preference and perceptions
scores), nonparametric (i.e., Mann-Whitney’s) tests
were used.
We also conducted an exploratory logistic regression
analysis to assess the predictors of enrollment to the
trial among the various risk and beneﬁt requirement
and perception scores, which were adjusted for demo-
graphic and clinical variables that were different
between the two groups in bivariate analysis (namely,
education and number of years with PD).
Results
Seventy-one subjects participated in our study: 61
enrollees and 10 decliners (Table 1). Enrollees and
decliners were similar in most respects, except that the
decliners had a higher level of education (P ¼ 0.05)
and had a trend toward longer period since diagnosis
(P ¼ 0.08).
Perception of and Attitude Toward Risks and
Beneﬁts
Enrollees and decliners differed in their perceptions
of, and tolerance for, risks (Table 2). Decliners per-
ceived the trials as carrying greater chance of harm
than did enrollees (15% versus 4% chance; P ¼
0.003). Decliners were willing to tolerate up to 11%
chance of a serious adverse event, whereas enrollees
were willing to tolerate up to 19% chance of such an
event (P ¼ 0.04).
In terms of perception of, and requirement for,
potential beneﬁts from the study intervention, enroll-
ees were willing to participate at a lower likelihood of
beneﬁt to self, as compared with decliners (21% ver-
sus 45%; P ¼ 0.01). However, enrollees and decliners
TABLE 1. Comparison of Demographic and Clinical
Characteristics Between Enrollees and Decliners
Characteristics
Enrollees
(N ¼ 61)
Decliners
(N ¼ 10) P Value*
Age (years; mean/SD) 59.2 (7.2) 61.7 (5.5) 0.24
Male (no./%) 40 (65.6) 8 (80.0) 0.48
Race (no./%)
White 59 (96.7) 9 (90.0) 0.37
Black 1 (1.6) 1 (10.0)
Asian 1 (1.6) 0
Years of education (no./%)
<High school 1 (1.7) 1 (10.0) 0.05
High school 15 (25.0) 1 (10.0)
Some college 10 (16.7) 1 (10.0)
College degree 25 (41.7) 2 (20.0)
Postcollege 9 (15.0) 5 (50.0)
Married (no./%) 44 (72.1) 8 (80.0) 0.72
Years since PD diagnosis
(mean/SD)
12.1 (4.3) 15.2 (4.7) 0.08
*Two-group t test for continuous variables and Fisher’s exact test for
categorical variables.
Abbreviation: SD, standard deviation.
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did not differ in terms of their perceptions of likeli-
hood of direct personal beneﬁt, with both groups giv-
ing fairly high median estimates of beneﬁt at 70% for
enrollees and 60% for decliners (P ¼ 0.15).
Both groups saw potential societal beneﬁt as quite
likely, but with enrollees perceiving a greater chance
of beneﬁt to society than decliners (88% versus 80%,
respectively; P ¼ 0.01). When asked about the mini-
mum likelihood of societal beneﬁt required for their
participation assuming they themselves would not ben-
eﬁt, there was no signiﬁcant difference between the
two groups. Enrollees would participate only if there
were a 90% chance or more of societal beneﬁt. The
decliners’ median score was 101 because the majority
said they would not participate when there was no
chance of direct personal beneﬁt, even if there were a
100% chance that researchers would make major
advancements in the treatment of PD as a result of the
trial.
In the logistic regression model that included all six
scores (correlations among which were modest, rang-
ing from 0.38 to 0.37, suggesting no collinearity
across predictors), which was adjusted for education
and years living with PD, only risk tolerance (odds ra-
tio [OR] ¼ 1.36; 95% conﬁdence interval [CI]: 1.05–
1.75) and perception (OR ¼ 0.77; 95% CI: 0.60–
0.99) scores signiﬁcantly predicted participation status.
The two variables from bivariate analysis—personal
beneﬁt requirement and societal beneﬁt perception
scores—that were signiﬁcantly different between
enrollees and decliners were not signiﬁcant in the mul-
tivariate model.
Ratings of Reasons For and Against
Participation
In their ratings of reasons against participation, enroll-
ees and decliners showed clear differences (Table 3). For
decliners, ‘‘It seems too dangerous’’ was a ‘‘strong rea-
son’’ not to participate, whereas for enrollees, it was a
‘‘minor reason’’ (3.7 versus 2.0; P < 0.001). A simi-
larly signiﬁcant difference was evident for the reason
‘‘I don’t like the idea of brain surgery.’’ Although
being a ‘‘guinea pig’’ and the burden of participating
in research were also rated higher as reasons against
participation by decliners than enrollees, both groups
tended to see these as minor reasons.
It is notable that the reason against participation
that was rated the lowest by both groups (in fact,
rated as ‘‘not a reason,’’ on average, by both groups)
was the fact that the purpose of the study was not
solely to beneﬁt the subjects directly.
In terms of reasons in favor of participation, enroll-
ees endorsed the reason ‘‘It’s better to do something
rather than just waiting for my PD to get worse’’ as a
‘‘strong reason’’ in favor of participation (mean score,
3.9), whereas decliners saw it as a ‘‘moderate reason’’
(mean, 3.0; P < 0.001). This was the top-rated reason
for participating for enrollees. Both enrollees and
decliners rated ‘‘I hope that it will help my PD’’ as a
strong reason in favor of participating, and there was
no signiﬁcant difference in the rating between the
groups. Altruistic reasons (e.g., ‘‘helping other patients
with PD’’ and ‘‘contribute to science’’) did not distin-
guish between the two groups, because both groups
rated these as"moderate’’ reasons in favor of partici-
pation. Enrollees more strongly endorsed the reasons
‘‘I expect it will help my PD’’ and ‘‘I need to try this
for the sake of my loved ones,’’ compared to decliners
(P ¼ 0.04 and 0.05, respectively), although these
TABLE 2. Comparison of Enrollee and Decliner Risk
Preference/Beneﬁt Requirement Scores and Risk/
Beneﬁt Perception Scores*
Variables
Enrollees
(N ¼ 61)
Decliners
(N ¼ 10) P Value**
Risk tolerance 19 (10–30) 11 (3–20) 0.040
Risk perception 4 (3–10) 15 (5–40) 0.003
Personal beneﬁt requirement 21 (20–30) 45 (20–93.5) 0.010
Personal beneﬁt perception 70 (50–75) 60 (50–70) 0.150
Societal beneﬁt requirement 90 (70–101) 101 (75–101) 0.240
Societal beneﬁt perception 87.5 (80–90) 80 (75–80) 0.010
*Scores are presented as median score (interquartile range).
**Mann-Whitney’s test.
TABLE 3. Comparison of Ratings of Reasons Against
and Reasons for Participation Between Enrollees and
Decliners*
Reasons
Enrollees
(N ¼ 61)
Decliners
(N ¼ 1 0)
P
Value**
Reasons against participation
It seems too dangerous. 2.0 (0.8) 3.7 (0.6) <0.001
I don’t like the idea of brain surgery. 2.5 (0.7) 3.4 (1.0) 0.003
I don’t want to be a guinea pig. 1.6 (0.7) 2.5 (1.1) 0.020
The purpose of the study was not
solely to beneﬁt me directly.
1.1 (0.3) 1.2 (0.4) 0.460
It seems like a lot of work for me to
be involved in this kind of study.
1.3 (0.5) 1.9 (0.9) 0.020
Reasons in favor of participation
I hope it will help my PD. 3.8 (0.4) 3.9 (0.3) 0.660
I would be helping other patients
with PD.
3.1 (0.8) 3.2 (0.9) 0.860
It’s better to do something rather
than just waiting for my PD to
get worse.
3.9 (0.3) 3.0 (0.9) <0.001
Maybe it might help me in the
long run, if the research succeeds.
3.0 (0.8) 2.4 (1.0) 0.080
I want to contribute to science. 2.9 (0.9) 2.7 (0.9) 0.470
I expect it will help my PD. 2.5 (1.1) 1.8 (0.9) 0.040
I need to try this for the sake of
my loved ones.
2.8 (1.0) 2.1 (1.1) 0.050
*Values are expressed as mean (standard deviation); range of scores: 1 ¼
not a reason; 2 ¼ minor reason; 3 ¼ moderate reason; 4 ¼ strong reason.
**Mann-Whitney’s test.
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reasons were at the bottom of the list for both groups
in terms of importance.
Discussion
There continues to be a concern that research sub-
jects enter even risky studies out of unrealistic desires
for therapeutic beneﬁt and that this clouds their
understanding of research design.1,7 We attempted to
address this concern by asking what distinguishes
those who enroll versus those who decline to partici-
pate in a sham surgery-controlled, randomized, trial
for PD.
Enrollees did not have more advanced disease;
indeed, there was a trend toward decliners having had
PD longer. This is consistent with our previous ﬁnding
using a hypothetical scenario, in which those willing
to participate in a phase I gene-transfer study of PD
had slightly milder disease.6 The decliners in our study
were more educated than the enrollees, although this
was because of half of the decliners having postcollege
education, rather than the enrollees being poorly edu-
cated; in fact, 57% of the enrollees had college educa-
tion or higher.
The risk/beneﬁt perception and requirement scores
and the ratings of reasons for and against participation
provided a coherent picture of why some volunteer for
sham surgery research while others do not. Although
unadjusted analysis showed that risk perception and
risk tolerance, as well as attitudes toward personal ben-
eﬁt and perceptions of societal beneﬁt, were different
between the two groups; the adjusted model showed
that only risk tolerance and risk perception scores were
predictive. This is consistent with the ratings of reasons
for and against participation, where the most robust
differences between the two groups had to do with per-
ception of danger and wariness toward brain surgery.
Further, the relatively high scores for perception of
potential personal beneﬁt (60%–70% chance) and soci-
etal beneﬁt (80%–88% chance) are congruent with rat-
ings of ‘‘hope of beneﬁt’’ and altruism being as
moderate to strong reasons, but they did not distinguish
between the groups. Although expectation of beneﬁt
was a stronger motivation for the enrollees, it was not
a strong reason overall.
Consistent with our previous study using a hypo-
thetical scenario, we found a signiﬁcantly greater
action orientation (e.g., ‘‘It’s better to do something
rather than just waiting for my PD to get worse’’)
among the enrollees than decliners.6
Another important ﬁnding is the juxtaposition of two
items: Though both groups gave the lowest rating (as a
reason against participation) to ‘‘The purpose of the
study was not solely to beneﬁt me directly,’’ they gave
their highest rating to ‘‘I hope it will help my PD’’ as a
reason in favor of participation. This provides evidence
that, consistent with other studies,3,8,9 research partici-
pants can understand that research is not solely to ben-
eﬁt them even though they may be motivated by hopes
of beneﬁt. As others have noted, it is important not to
assume that being motivated by a desire for beneﬁt
implies a faulty understanding of research9,10—just as
one can rationally buy a lottery ticket desiring to win,
all the while understanding that a lottery’s purpose is
not to enrich the buyer of tickets, but rather to raise
funds. Supporting this interpretation is the fact that the
respondents clearly distinguished between hope and ex-
pectation of beneﬁt and gave higher ratings to altruistic
and proscience reasons than to ‘‘expect to beneﬁt’’ as a
reason for participation.
This study had limitations. First, because we inter-
viewed actual enrollees and decliners, the numbers
were quite small. This was especially true for the
decliner group—which consisted of only 10 subjects—
because it is relatively uncommon for persons who
seek out and have discussions about a research study
to decline. On the other hand, it may be that the dif-
ferences between enrollees and decliners we found
were conservative estimates, given that decliners who
are still willing to be interviewed may be more prore-
search. Second, the interviews were retrospective and
may have been colored by the actual decisions made
as well as the passage of time. However, the results of
this study are quite similar to our prospective (but hy-
pothetical scenario-based) study comparing those who
were willing and unwilling to participate in a neuro-
surgical gene-transfer study for PD.6 Both studies, for
example, found that the most potent predictors of par-
ticipation were risk perception and risk tolerance,
along with an action orientation. Third, any study
eliciting layperson estimates of probabilities must
acknowledge the well-known limitations of such exer-
cises,11 such as the lay public’s tendency to use proba-
bility statements for nonmathematical purposes.12
Thus, we emphasize not the absolute numbers, but
rather the relative comparison between the two
groups. For example, the relatively high estimates of
potential personal beneﬁt given by both groups must
be interpreted in light of the fact that both groups
clearly endorsed ‘‘hope’’ for beneﬁt as a stronger rea-
son for participation than ‘‘expectation’’ of beneﬁt.
Although both risk and beneﬁt information are im-
portant, they are important in different ways. When
discussing risks, researchers should be aware that such
information may indeed be the pivotal factor in a
patient’s decision to participate. This creates a height-
ened responsibility to ensure that risk information is
both user-friendly and accurate and not simply a cata-
log of items to fulﬁll regulatory requirements. In
regard to beneﬁt information, researchers should
assume that most potential subjects (whether they end
up enrolling or not) will be motivated by hope for
beneﬁt. The focus should be not on eradicating this
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orientation, but on ensuring that it does not lead to a
misunderstanding; this can be accomplished by
acknowledging the subjects’ therapeutic motivation
while contrasting it with the scientiﬁc purpose of the
study’s aims and design.3 Optimal informed consent
for therapeutic intervention trials, especially when dis-
ease-altering treatments do not exist, will require
working with the therapeutic orientation of subjects
rather than ignoring or working against it.
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